Lineage Cell Therapeutics (LCTX) Net Margin Growth (3y) (2013 - 2026)

Lineage Cell Therapeutics (LCTX) Net Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -374.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -44.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -759,845.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,793.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 82,312.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -5,319.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,934.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 31,387.00
10 Lineage Cell Therapeutics 270.61 Mn 212.77 Mn 1.07 Mn -129,910.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -129,910.00
Mar 31, 2026 -9,438.00
Dec 31, 2025 22,631.00
Sep 30, 2025 -30,937.00
Jun 30, 2025 -66,605.00
Mar 31, 2025 -31,796.00
Dec 31, 2024 -5,730.00
Sep 30, 2024 26,570.00
Jun 30, 2024 55,971.00
Mar 31, 2024 -8,382.00
Dec 31, 2023 -50,295.00
Sep 30, 2023 81,782.00
Jun 30, 2023 153,038.00
Mar 31, 2023 145,511.00
Dec 31, 2022 -102,847.00
Sep 30, 2022 306,121.00
Jun 30, 2022 402,511.00
Mar 31, 2022 -342,510.00
Dec 31, 2021 592,419.00
Sep 30, 2021 -712,148.00